Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells
Abstract Chimeric antigen receptor (CAR)-T therapy requires autologous T lymphocytes from cancer patients, a process that is both costly and complex. Universal CAR-T cell treatment from allogeneic sources can overcome this limitation but is impeded by graft-versus-host disease (GvHD) and host versus...
Main Authors: | Yixi Zhang, Hongyu Fang, Guocan Wang, Guangxun Yuan, Ruoyu Dong, Jijun Luo, Yu Lyu, Yajie Wang, Peng Li, Chun Zhou, Weiwei Yin, Haowen Xiao, Jie Sun, Xun Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-12-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-44176-0 |
Similar Items
-
Nephrotoxicity of Cyclosporine A and Amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation
by: K Furrer, et al.
Published: (2002-06-01) -
CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
by: Hongwen Li, et al.
Published: (2023-08-01) -
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
by: Zixin Lv, et al.
Published: (2023-07-01) -
Allogeneic CAR-T Cells: More than Ease of Access?
by: Charlotte Graham, et al.
Published: (2018-10-01) -
Mechano-boosting nanomedicine antitumour efficacy by blocking the reticuloendothelial system with stiff nanogels
by: Zheng Li, et al.
Published: (2023-03-01)